Parkinsons disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra. This lowers the concentration of dopamine in the striatum by 80%. This decrease in dopamine levels leads to symptoms associated with PD such as tremors, bradykinesia, and muscular rigidity. It is usually diagnosed after the age of 50 years; however, cases of earlier incidence have also been reported.

Covered in this report The report covers the present scenario and the growth prospects of the global parkinson’s disease (PD) drugs market for 2017-2021. To calculate the market size, the report considers sales/revenues and market share of the PD drugs.

The market is divided into the following segments based on geography: AmericasAPACEMEA

Technavio’s report, Global Parkinson’s Disease (PD) Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key questions answered in this report What will the market size be in 2020 and what will the growth rate be?What are the key market trends?What is driving this market?What are the challenges to market growth?Who are the key vendors in this market space?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.